This Dry Powder Inhalers training session on future pulmonary delivery will give you a clear orientation for your actual or future developments in this area in terms of formulation and product and new product launching possibilities.
Pulmonary delivery is a very attractive and not yet fully developed way for several drugs and peptides thinking in an alternative for more difficult administration pathway such as injectable. Other pulmonary delivery systems like metered dose inhalers present some disadvantages in terms of manufacturing equipments, production plant and technology. This session will give you a clear orientation for your actual or future developments in this area in terms of formulation and product and new product launching possibilities.
Areas Covered in the seminar:
- Reasons to develop a product in a Dry Powder Inhaler.
- Research and Development of a dry powder inhaler formulation.
- Scaling Up of a Dry Powder Inhaler formulation.
- Achieving drug dose uniformity at a microgram level.
- Encapsulation equipment needed to achieve low dose encapsulating weights.
- Dry Powder Inhalers devices : Development and patentability.
Who will benefit:
This Webinar will offer those involved in New Product Development in the bio-pharmaceutical industry the possibility to consider this growing technology to vehiculize drugs to the lungs:
- R&D Professionals
- R&D Technical people
- Excipient Suppliers for DPI
- Pharma Consultants
- New Product Project Developers
Instructor Profile:
Claudio Cerati, is a pharmacist and Director of Research and Development Department at Tecnoquimicas SA in the city of Cali, Colombia was the head of a Dry Powder Inhaler project at Phoenix Laboratories Argentina . He is also consultant of exipients manufactuing firms directly related to Dry Powder Inhaler formulation and scale up with operations in Latin America.
During the last twenty five years , he was directly involved in R&D, Quality Control and Manufacturing areas in national and multinational companies in Latin America ( Argentina and Brazil) with the direct responsibility of developing and scaling up pharmaceutical processes.
